• Acurx Successfully Completes Ph1 Clinical Trial for ACX-362E in CDI americanpharmaceuticalreview
    September 03, 2019
    Acurx Pharmaceuticals announced its lead product candidate, ACX-362E, has successfully completed the 68-subject, double-blind, placebo-controlled, multiple-ascending dose Phase 1 clinical trial of ACX-362E in healthy volunteers.
PharmaSources Customer Service